Articles related to RARE CONDITIONS & DISEASES

The diagnosis and treatment of mantle cell lymphoma are covered in this podcast by Jonathon Cohen, MD, MS, Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine. He also discusses how BTK inhibitors and CAR T-cell therapy are changing the treatment landscape and what he expects will be presented at upcoming conferences.

A mass measuring 4.8 cm by 5.0 cm by 3.9 cm was detected by transabdominal and transvaginal ultrasonography of the abdomen and pelvis. This mass was located along the posterior part of the right hepatic lobe. Following the clinic evaluation, there were two important questions to answer. Initially, was the adrenal tumor malignant or benign? Second, did the lesion secrete hormones?

Although the relationship between preceding viral illness and subsequent Guillain-Barre isn’t proven, it is a commonly observed pattern. The severity of GBS ranges from mild sensory disturbances to life-threatening loss of function requiring intubation.

The first treatment for light-chain amyloidosis was approved by the FDA in 2021. Daratumumab-based regimens produce profound hematologic and organ responses, providing a new therapeutic foundation. Early detection, correct fibril typing, the challenges of the very advanced patient, and the lack of therapies to remove amyloid deposits are all being researched but remain elusive.

The Hall-of-Fame quarterback recently alerted worried viewers about the diagnosis of the rare disease after he felt some pain in his neck. Ultimately, the diagnosis changed his outlook on life. “We’re going to go to Europe, going to go to Paris, going to go to wherever we want to go. I’m going to get all this in because I feel like I don’t want to put this off anymore … I may have 25, 30 years left, but I’m going to act like I got one.” Terry Bradshaw

Judith Trotman, MBChB, FRACP, FRCPA, clinical professor at the University of Sydney in Concord, New South Wales, Australia, and head of the Hematology Department at Concord Repatriation General Hospital, provides background on mantle cell lymphoma, its unique treatment challenges, and the significance of the SHINE trial, which assessed ibrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma.